Treating Myelofibrosis is not a one-size-fits-all process. Because the disease can range from mild and slow-growing to aggressive, your treatment plan must be as unique as your DNA. At Liv Hospital, we follow a dual approach: Managing Symptoms to improve your daily quality of life, and Curative Interventions to potentially eliminate the disease entirely.
Our multidisciplinary Tumor Board evaluates your specific “Risk Score” (DIPSS Plus) to determine the right moment to intervene. Whether you need advanced drug therapy to shrink an enlarged spleen or a complex Allogeneic Stem Cell Transplant, our infrastructure is designed to deliver US-standard care with the speed and hospitality Turkey is known for.
Send us all your questions or requests, and our expert team will assist you.
Treatment and Procedures
Treating Myelofibrosis is not a one size fits all process. Because the disease can range from mild and slow-growing to aggressive, your treatment plan must be as unique as your DNA. At Liv Hospital, we follow a dual approach: Managing Symptoms to improve your daily quality of life, and Curative Interventions to potentially eliminate the disease entirely.
Our multidisciplinary Tumor Board evaluates your specific “Risk Score” (DIPSS Plus) to determine the right moment to intervene. Whether you need advanced drug therapy to shrink an enlarged spleen or a complex Allogeneic Stem Cell Transplant, our infrastructure is designed to deliver US-standard care with the speed and hospitality Turkey is known for.
For Low-Risk Patients : If you do not have symptoms (asymptomatic) and your blood counts are relatively stable, you may not need immediate treatment. This is not “doing nothing”; it is Active Surveillance.
For Intermediate and High-Risk Patients : The discovery of the JAK1 and JAK2 gene mutations changed the landscape of Myelofibrosis treatment. Targeted therapies are oral medications (pills) that block the specific pathways causing inflammation and cell overgrowth.
Note: These drugs do not “cure” the bone marrow scarring, but they manage the disease excellently, allowing patients to live relatively normal lives.
Fatigue caused by anemia is often the most debilitating symptom. We use a combination of therapies to boost your red blood cell count:
When the spleen becomes massive, it presses on the stomach causing pain and early fullness. If JAK inhibitors are not enough, we consider:
Send us all your questions or requests, and our expert team will assist you.
Currently, an Allogeneic Stem Cell Transplant (Bone Marrow Transplant) is the only potential cure for Myelofibrosis. It is the only method that can replace scarred marrow with healthy, blood-producing cells.
Who is a candidate? We generally recommend this for “Intermediate-2” or “High-Risk” patients who are fit enough to handle the procedure.
The Procedure Steps:
The Liv Hospital Advantage: CD34+ Selection One of the biggest risks of transplant is Graft versus Host Disease (GVHD), where donor cells attack the patient. Liv Hospital utilizes CD34+ Immunomagnetic Cell Selection. This technology “cleans” the donor graft, removing the immune cells that cause GVHD while keeping the stem cells that cure the cancer. This allows for safer transplants even when a perfect donor match isn’t available (Haploidentical Transplant).
Treating cancer is important, but treating the person is vital. Palliative care is not just for end of life; it is an extra layer of support provided alongside curative treatment.
Yes. An Allogeneic Stem Cell Transplant is the only curative treatment. It replaces the fibrotic marrow with healthy donor cells.
Common side effects include bruising, dizziness, and a temporary drop in platelet counts. It can also increase the risk of specific infections (like shingles), so we monitor you closely.
Yes. Age is less important than your overall fitness. We use “Reduced Intensity Conditioning” (RIC) which uses gentler chemotherapy, making the cure accessible to older adults up to age 75.
Low-risk patients can live for years without treatment. However, high-risk disease can progress to Acute Leukemia (AML) or bone marrow failure if left untreated.
The hospital stay is typically 4 to 6 weeks. However, international patients should plan to stay in Turkey for roughly 3 months for essential safety monitoring after discharge.
Your Comparison List (you must select at least 2 packages)
